Kiora Pharmaceuticals (KPRX) Asset Writedowns and Impairment (2015 - 2025)

Kiora Pharmaceuticals (KPRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $4.6 million in Q4 2025.

• Quarterly Asset Writedowns and Impairment rose 341.62% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (up 134.72% YoY) and the FY2025 annual result came in at $4.6 million, up 4315.99% from the prior year.
• Asset Writedowns and Impairment rose to $4.6 million in Q4 2025, from -$1.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $4.6 million in Q4 2025 to a low of -$1.9 million in Q4 2024.
• A 3-year average of $1.3 million and a median of $1.9 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment slumped 44031.5% — and 2025, when it soared 341.62%.
• Tracing KPRX's Asset Writedowns and Impairment over 3 years: stood at -$4314.0 in 2023, then tumbled by 44031.5% to -$1.9 million in 2024, then surged by 341.62% to $4.6 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $4.6 million (Q4 2025), -$1.9 million (Q4 2024), and $2.0 million (Q3 2024), per Business Quant data.